drugset / Trial / NCT04172779
Erlotinib for Hepatocellular Carcinoma Chemoprevention
Phase 2
Not yet recruiting
60 enrolled
University of Texas Southwestern Medical Center
National Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
Timeline
- Start
- 2026-12
- Primary completion
- 2030-06
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 50 mg | Oral |